Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Tempol prevents cardiac oxidative damage and left ventricular dysfunction in the PPAR-α KO mouse.

Guellich A, Damy T, Conti M, Claes V, Samuel JL, Pineau T, Lecarpentier Y, Coirault C.

Am J Physiol Heart Circ Physiol. 2013 Jun 1;304(11):H1505-12. doi: 10.1152/ajpheart.00669.2012. Epub 2013 Mar 29.

2.

Role of oxidative stress in cardiac dysfunction of PPARalpha-/- mice.

Guellich A, Damy T, Lecarpentier Y, Conti M, Claes V, Samuel JL, Quillard J, Hébert JL, Pineau T, Coirault C.

Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H93-H102. Epub 2007 Mar 16.

3.

Oxidative stress contributes to methamphetamine-induced left ventricular dysfunction.

Lord KC, Shenouda SK, McIlwain E, Charalampidis D, Lucchesi PA, Varner KJ.

Cardiovasc Res. 2010 Jul 1;87(1):111-8. doi: 10.1093/cvr/cvq043. Epub 2010 Feb 5.

4.

The antioxidant tempol attenuates pressure overload-induced cardiac hypertrophy and contractile dysfunction in mice fed a high-fructose diet.

Chess DJ, Xu W, Khairallah R, O'Shea KM, Kop WJ, Azimzadeh AM, Stanley WC.

Am J Physiol Heart Circ Physiol. 2008 Dec;295(6):H2223-30. doi: 10.1152/ajpheart.00563.2008. Epub 2008 Oct 17.

5.

Increased entropy production in diaphragm muscle of PPAR alpha knockout mice.

Lecarpentier Y, Krokidis X, Martin P, Pineau T, Hébert JL, Quillard J, Cortes-Morichetti M, Coirault C.

J Theor Biol. 2008 Jan 7;250(1):92-102. Epub 2007 Sep 21.

6.

Cardiac and renal antioxidant enzymes and effects of tempol in hyperthyroid rats.

Moreno JM, Rodríguez Gómez I, Wangensteen R, Osuna A, Bueno P, Vargas F.

Am J Physiol Endocrinol Metab. 2005 Nov;289(5):E776-83. Epub 2005 Jun 7.

7.

Activation of PPAR-α in the early stage of heart failure maintained myocardial function and energetics in pressure-overload heart failure.

Kaimoto S, Hoshino A, Ariyoshi M, Okawa Y, Tateishi S, Ono K, Uchihashi M, Fukai K, Iwai-Kanai E, Matoba S.

Am J Physiol Heart Circ Physiol. 2017 Feb 1;312(2):H305-H313. doi: 10.1152/ajpheart.00553.2016. Epub 2016 Dec 23.

PMID:
28011586
8.

TNF-alpha-induced mitochondrial oxidative stress and cardiac dysfunction: restoration by superoxide dismutase mimetic Tempol.

Mariappan N, Soorappan RN, Haque M, Sriramula S, Francis J.

Am J Physiol Heart Circ Physiol. 2007 Nov;293(5):H2726-37. Epub 2007 Aug 3.

9.

The benefit of medium-chain triglyceride therapy on the cardiac function of SHRs is associated with a reversal of metabolic and signaling alterations.

Iemitsu M, Shimojo N, Maeda S, Irukayama-Tomobe Y, Sakai S, Ohkubo T, Tanaka Y, Miyauchi T.

Am J Physiol Heart Circ Physiol. 2008 Jul;295(1):H136-44. doi: 10.1152/ajpheart.01417.2006. Epub 2008 May 2.

10.

Antioxidant enzymes and effects of tempol on the development of hypertension induced by nitric oxide inhibition.

Sainz J, Wangensteen R, Rodríguez Gómez I, Moreno JM, Chamorro V, Osuna A, Bueno P, Vargas F.

Am J Hypertens. 2005 Jun;18(6):871-7.

PMID:
15925750
11.

Adiponectin protects against angiotensin II-induced cardiac fibrosis through activation of PPAR-alpha.

Fujita K, Maeda N, Sonoda M, Ohashi K, Hibuse T, Nishizawa H, Nishida M, Hiuge A, Kurata A, Kihara S, Shimomura I, Funahashi T.

Arterioscler Thromb Vasc Biol. 2008 May;28(5):863-70. doi: 10.1161/ATVBAHA.107.156687. Epub 2008 Feb 28.

12.

Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice.

Verreth W, De Keyzer D, Pelat M, Verhamme P, Ganame J, Bielicki JK, Mertens A, Quarck R, Benhabilès N, Marguerie G, Mackness B, Mackness M, Ninio E, Herregods MC, Balligand JL, Holvoet P.

Circulation. 2004 Nov 16;110(20):3259-69. Epub 2004 Nov 8.

13.

The antioxidant tempol inhibits cardiac hypertrophy in the insulin-resistant GLUT4-deficient mouse in vivo.

Ritchie RH, Quinn JM, Cao AH, Drummond GR, Kaye DM, Favaloro JM, Proietto J, Delbridge LM.

J Mol Cell Cardiol. 2007 Jun;42(6):1119-28. Epub 2007 Mar 27.

PMID:
17490678
14.

Renal and metabolic effects of tempol in obese ZSF1 rats--distinct role for superoxide and hydrogen peroxide in diabetic renal injury.

Rafikova O, Salah EM, Tofovic SP.

Metabolism. 2008 Oct;57(10):1434-44. doi: 10.1016/j.metabol.2008.05.014.

PMID:
18803950
15.

Downregulation of peroxisome proliferator-activated receptor-alpha gene expression in a mouse model of ischemic cardiomyopathy is dependent on reactive oxygen species and prevents lipotoxicity.

Dewald O, Sharma S, Adrogue J, Salazar R, Duerr GD, Crapo JD, Entman ML, Taegtmeyer H.

Circulation. 2005 Jul 19;112(3):407-15. Epub 2005 Jul 11.

16.

Chronic Tempol treatment restores pharmacological preconditioning in the senescent rat heart.

Zhu J, Rebecchi MJ, Wang Q, Glass PS, Brink PR, Liu L.

Am J Physiol Heart Circ Physiol. 2013 Mar 1;304(5):H649-59. doi: 10.1152/ajpheart.00794.2012. Epub 2012 Dec 28.

17.
18.

Control of cardiac pyruvate dehydrogenase activity in peroxisome proliferator-activated receptor-alpha transgenic mice.

Hopkins TA, Sugden MC, Holness MJ, Kozak R, Dyck JR, Lopaschuk GD.

Am J Physiol Heart Circ Physiol. 2003 Jul;285(1):H270-6. Epub 2003 Mar 27.

19.

Inhibition of lipid infusion-induced skeletal muscle insulin resistance by cotreatment with tempol and glutathione in mice.

Kim BS, Cha HN, Kim YW, Kim JY, Dan JM, Park SY.

J Pharmacol Sci. 2009 Jul;110(3):370-80.

20.

Angiotensin converting enzyme inhibitor prevents left ventricular remodelling after myocardial infarction in angiotensin II type 1 receptor knockout mice.

Yoshiyama M, Nakamura Y, Omura T, Izumi Y, Matsumoto R, Oda S, Takeuchi K, Kim S, Iwao H, Yoshikawa J.

Heart. 2005 Aug;91(8):1080-5.

Supplemental Content

Support Center